Eligo Bioscience has a total of 192 patents globally, out of which 45 have been granted. Of these 192 patents, more than 77% patents are active. United States of America is where Eligo Bioscience has filed the maximum number of patents, followed by Europe (EPO) and Japan. Parallelly, United States of America seems to be the main focused R&D centre and France is the origin country of Eligo Bioscience.
Eligo Bioscience founded in 2014 by Timothy Lu, Luciano Marraffini, David Bikard, and Xavier Duportet, is a Paris-based biotechnology company specializing in precision microbiome engineering. Leveraging synthetic biology and CRISPR-Cas technology, Eligo develops sequence-specific antimicrobials that selectively eliminate harmful bacteria while preserving beneficial strains. The company focuses on treating bacteria-associated diseases and serves a global market.
Do read about some of the most popular patents of Eligo Bioscience which have been covered by us in this article and also you can find Eligo Bioscience patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Eligo Bioscience patent portfolio.
How many patents does Eligo Bioscience have?
Eligo Bioscience has a total of 192 patents globally. These patents belong to 17 unique patent families. Out of 192 patents, 148 patents are active.
How Many Patents did Eligo Bioscience File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Eligo Bioscience Applications Filed | Eligo Bioscience Patents Granted |
| 2025 | 1 | 6 |
| 2024 | 13 | 10 |
| 2023 | 15 | 17 |
| 2022 | 40 | 8 |
| 2021 | 54 | 3 |
| 2020 | 26 | 1 |
| 2019 | 24 | – |
| 2018 | 14 | – |
| 2017 | 1 | – |
| 2016 | 4 | – |
How many Eligo Bioscience patents are Alive/Dead?
Worldwide Patents
How Many Patents did Eligo Bioscience File in Different Countries?
Countries in which Eligo Bioscience Filed Patents
| Country | Patents |
| United States of America | 55 |
| Europe (EPO) | 20 |
| Japan | 15 |
| Israel | 15 |
| Canada | 14 |
| China | 13 |
| Korea (South) | 13 |
| Hong Kong (S.A.R.) | 12 |
| Germany | 5 |
| Denmark | 4 |
| Spain | 1 |
Where are Research Centres of Eligo Bioscience Patents Located?
10 Best Eligo Bioscience Patents
US20180200342A1 is the most popular patent in the Eligo Bioscience portfolio. It has received 115 citations so far from companies like Snipr Technologies, and Inscripta.
Below is the list of 10 most cited patents of Eligo Bioscience:
| Publication Number | Citation Count |
| US20180200342A1 | 115 |
| WO2017009399A1 | 109 |
| US12214022B2 | 16 |
| CN115427565A | 15 |
| WO2021250284A1 | 14 |
| CN110268062A | 12 |
| EP3922719A1 | 9 |
| US11541106B2 | 7 |
| WO2020128108A1 | 7 |
| WO2018141907A1 | 7 |
What Percentage of Eligo Bioscience US Patent Applications were Granted?
Eligo Bioscience (Excluding its subsidiaries) has filed 52 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 32 have been granted leading to a grant rate of 88.89%.
Below are the key stats of Eligo Bioscience patent prosecution at the USPTO.
Which Law Firms are managing US Patents for Eligo Bioscience?
| Law Firm | Total Applications | Success Rate |
| Arrigo Lee Guttman & Mouta Bellum Llp | 47 | 93.75% |
| Carter Deluca & Farrell Llp | 5 | 50.00% |
What are Eligo Bioscience key innovation segments?
What Technologies are Covered by Eligo Bioscience?
The chart below distributes patents filed by Eligo Bioscience in different countries on the basis of the technology protected in patents. It also represents the markets where Eligo Bioscience thinks it’s important to protect particular technological inventions.
R&D Focus: How has Eligo Bioscience search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Eligo Bioscience?
